Diseases covered by patents & 2M shares license payment from NNVC Sept. 30, 2013 10Q filing (excerpt below).
So it looks like the license cost would be somewhat dilutive to the rest of company shareholders in the event of a sale of the company or sale/license of substantially all of IP. That would amount to four times 2M = 8M additional shares in addition to 50M total outstanding shares of NNVC existing today or ~16% dilution to share price upon sale of the company. Seems reasonable considering the key value of the company is the intellectual property. It wouldn't exist or be valuable without it.